Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1209 in Homozygous Familial Hypercholesterolemia
NCT04455581Phase 2Unknown
- Sponsor
- Hengrui
- Start
- Sep 2020
- Primary completion
- Jun 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of recaticimab in familial hypercholesterolemia (FH), sponsored by Hengrui. Primary endpoint: Percent Change from Baseline in LDL-C at 12 weeks. Status: unknown.
02
Drugs
recaticimab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NCT04455581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04455581.